INOVIO Announces Pricing of $30 Million Public Offering

Stock Information for Kronos Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Kronos Bio Inc.

INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights
INOVIO to Present at Upcoming Scientific and Investor Conferences
INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025
INOVIO to Present at Upcoming Scientific Conferences
INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19
INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025
Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.